MXCT
MaxCyte, Inc.
MXCT lost money over the past year, so it has no meaningful PE right now.
MXCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MXCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
MXCT PE Valuation
MXCT has no meaningful PE right now: it lost money over the past year.
MXCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect MXCT's revenue to grow, with its earnings and profitability holding steady.
MXCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.25 | +$0.19 |
| Q2 2026 | -$0.32 | +$0.11 |
| Q1 2026 | -$0.36 | +$0.04 |
| Q4 2025 | -$0.42 | -$0.03 |
| Q3 2025 | -$0.44 | -$0.10 |
| Q2 2025 | -$0.43 | -$0.09 |
| Q1 2025 | -$0.40 | -$0.05 |
| Q4 2024 | -$0.39 | -$0.02 |
MXCT is still losing money, but less than at its worst: $0.25 per share over the past year, against $0.44 at its worst in late 2025.
MXCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | +49% |
| Q2 2026 | $7.3M | -15% |
| Q1 2026 | $9.7M | -7.1% |
| Q4 2025 | $7.3M | -16% |
| Q3 2025 | $6.8M | -16% |
| Q2 2025 | $8.5M | -18% |
| Q1 2025 | $10.4M | -8.4% |
| Q4 2024 | $8.7M | -45% |
MXCT's revenue is recovering but still below its 2023 peak: $10M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +148 points |
| Q2 2026 | -141% | +27 points |
| Q1 2026 | -64% | +54 points |
| Q4 2025 | -154% | -5.4 points |
| Q3 2025 | -207% | -35 points |
| Q2 2025 | -167% | -53 points |
| Q1 2025 | -118% | -10 points |
| Q4 2024 | -148% | -97 points |
MXCT's operating margin was −60% last quarter, up 148 points from the same quarter a year ago.
MXCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | +$2.2M |
| Q2 2026 | -$4.7M | +$5.7M |
| Q1 2026 | -$8.2M | +$6.8M |
| Q4 2025 | -$2.9M | +$5M |
| Q3 2025 | -$7.8M | -$3M |
| Q2 2025 | -$10.4M | -$5.3M |
| Q1 2025 | -$15.1M | -$3.7M |
| Q4 2024 | -$8M | -12010% |
MXCT has burned cash in almost every quarter: −$21M over the past year, against −$41M the year before.
MXCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.1% | -3.3M shares |
| 1 year | -2.9% | -3.1M shares |
| 3 years | +0.1% | +88.2K shares |
| 5 years | +22% | +18.8M shares |
| Available history | +80% | +46.1M shares |
MXCT has 104M diluted shares, down 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
MXCT Net Leverage
MXCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MXCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.2 | Neutral |
| Stochastic | 49.8 | Neutral |
MXCT's weekly RSI is 49 (neutral) and its Stochastic is 50 (neutral).
MXCT PE vs Healthcare Sector
MXCT has no meaningful PE right now: it lost money over the past year.
MXCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 4.8% below |
| 20 week MA | $1.23 | 3.3% below |
| 50 week MA | $1.12 | 6.2% above |
| 100 week MA | $1.84 | 35% below |
| 200 week MA | $3.06 | 61% below |
MXCT's trend is mixed: it's above one of its five weekly moving averages, and 61% below its 200-week average.
MXCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.0 | $10.8 | -36% |
| 2022 | $10.8 | $5.01 | -54% |
| 2023 | $5.01 | $4.70 | -6.2% |
| 2024 | $4.70 | $4.13 | -12% |
| 2025 | $4.13 | $1.61 | -61% |
| 2026 YTD | $1.61 | $1.19 | -26% |
MXCT has finished every year since 2021 lower, and it's down 26% so far in 2026.